(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.29%.
Palvella Therapeutics's earnings in 2025 is -$26,608,000.On average, 8 Wall Street analysts forecast PVLA's earnings for 2025 to be -$35,598,850, with the lowest PVLA earnings forecast at -$37,602,861, and the highest PVLA earnings forecast at -$31,741,239. On average, 8 Wall Street analysts forecast PVLA's earnings for 2026 to be -$35,211,761, with the lowest PVLA earnings forecast at -$45,344,627, and the highest PVLA earnings forecast at -$19,686,204.
In 2027, PVLA is forecast to generate -$49,281,867 in earnings, with the lowest earnings forecast at -$60,496,368 and the highest earnings forecast at -$41,584,340.